Is Your Specialty Rx Strategy Acting as a “Profit Center” for your PBM?

Posted on Posted in Pharmacy Benefits Newsletters


At a recent Morgan Stanley conference, the following key trends in the marketplace were discussed:

Specialty is the future and CVS is 1-2 years ahead of competition. Attention was drawn to CVS’ Novologix acquisition, which gives it a toehold in processing specialty medical claims under the pharmacy benefit and Coram which extends CVS’ specialty reach.

Read More